Squalene synthase: A critical enzyme in the cholesterol biosynthesis pathway

Clinical Genetics

Volumn 75, Issue 1, 2009, Pages 19-29

  Do, R ^a   Kiss, R S ^a   Gaudet, D ^b   Engert, Jamie C ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cholesterol biosynthesis; FDFT1; Hypercholesterolemia; Squalene synthase

Indexed keywords

ATORVASTATIN; BMS 188494; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; RPR 107393; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; T 91485; TAK 475; UNCLASSIFIED DRUG; YM 53601; ZARAGOZIC ACID A;

ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; LINKAGE ANALYSIS; MYOPATHY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIDE EFFECT;

ANIMALS; CHOLESTEROL; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; GENETIC VARIATION; HUMANS; HYPERCHOLESTEROLEMIA; LINKAGE DISEQUILIBRIUM; PHENOTYPE;

EID: 58149202133     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2008.01099.x     Document Type: Review

References (93)

1. Pandit J, Danley DE, Schulte GK et al. Crystal structure of human squalene synthase. A key enzyme in cholesterol biosynthesis. J Biol Chem 2000: 275: 30610-30617.
2. Tansey TR, Shechter I. Squalene synthase: Structure and regulation. Prog Nucleic Acid Res Mol Biol 2001: 65: 157-195.
3. Davidson MH. Squalene synthase inhibition: A novel target for the management of dyslipidemia. Curr Atheroscler Rep 2007: 9: 78-80.
4. Okada S, Devarenne TP, Chappell J. Molecular characterization of squalene synthase from the green microalga Botryococcus braunii, race B. Arch Biochem Biophys 2000: 373: 307-317.
5. Olivier LM, Kovacs W, Masuda K et al. Identification of peroxisomal targeting signals in cholesterol biosynthetic enzymes. AA-CoA thiolase, hmg-coa synthase, MPPD, and FPP synthase. J Lipid Res 2000: 41: 1921-1935.
6. Stamellos KD, Shackelford JE, Shechter I et al. Subcellular localization of squalene synthase in rat hepatic cells. Biochemical and immunochemical evidence. J Biol Chem 1993: 268: 12825-12836.
7. Summers C, Karst F, Charles AD. Cloning, expression and characterisation of the cDNA encoding human hepatic squalene synthase, and its relationship to phytoene synthase. Gene 1993: 136: 185-192.
8. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990: 343: 425-430.
9. Kennedy MA, Barbuch R, Bard M. Transcriptional regulation of the squalene synthase gene (ERG9) in the yeast Saccharomyces cerevisiae. Biochim Biophys Acta 1999: 1445: 110-122.
10. Robinson GW, Tsay YH, Kienzle BK et al. Conservation between human and fungal squalene synthetases: Similarities in structure, function, and regulation. Mol Cell Biol 1993: 13: 2706-2717.
11. Paradise EM, Kirby J, Chan R et al. Redirection of flux through the FPP branch-point in Saccharomyces cerevisiae by downregulating squalene synthase. Biotechnol Bioeng 2008: 100(2): 371-378.
12. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976: 72: 323-326.
13. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006: 124: 35-46.
14. Sun LP, Li L, Goldstein JL et al. Insig required for sterol-mediated inhibition of Scap/SREBP binding to COPII proteins in vitro. J Biol Chem 2005: 280: 26483-26490.
15. Adams CM, Goldstein JL, Brown MS. Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles. Proc Natl Acad Sci U S A 2003: 100: 10647-10652.
16. Gong Y, Lee JN, Lee PC et al. Sterol-regulated ubiquitination and degradation of Insig-1 creates a convergent mechanism for feedback control of cholesterol synthesis and uptake. Cell Metab 2006: 3: 15-24.
17. Brown MS, Ye J, Rawson RB et al. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans. Cell 2000: 100: 391-398.
18. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A 1999: 96: 11041-11048.
19. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002: 109: 1125-1131.
20. Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997: 89: 331-340.
21. Guan G, Dai PH, Osborne TF et al. Multiple sequence elements are involved in the transcriptional regulation of the human squalene synthase gene. J Biol Chem 1997: 272: 10295-10302.
22. Tansey TR, Shechter I. Structure and regulation of mammalian squalene synthase. Biochim Biophys Acta 2000: 1529: 49-62.
23. Armitage J. The safety of statins in clinical practice. Lancet 2007: 370: 1781-1790.
24. Kovanen PT, Bilheimer DW, Goldstein JL et al. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci U S A 1981: 78: 1194-1198.
25. Ma PT, Gil G, Sudhof TC et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A 1986: 83: 8370-8374.
26. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol 1988: 62: 10J-15J.
27. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004: 110: 227-239.
28. Mishra TK, Routray S. Current perspectives on statins. J Indian Med Assoc 2003: 101: 381-383.
29. Huynh T, Cordato D, Yang F et al. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J 2002: 32: 486-490.
30. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003: 289: 1681-1690.
31. De Pinieux G, Chariot P, Ammi-Said M et al. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996: 42: 333-337.
32. Gaist D, Rodriguez LA, Huerta C et al. Lipid-lowering drugs and risk of myopathy: A population-based follow-up study. Epidemiology 2001: 12: 565-569.
33. Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999: 22: 295-297.
34. Levy HB, Kohlhaas HK. Considerations for supplementing with coenzyme Q10 during statin therapy. Ann Pharmacother 2006: 40: 290-294.
35. Christopher-Stine L. Statin myopathy: An update. Curr Opin Rheumatol 2006: 18: 647-653.
36. Stein E, Stender S, Mata P et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004: 148: 447-455.
37. Masaki N, Tatami R, Kumamoto T et al. Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy. Int Heart J 2005: 46: 833-843.
38. Kastelein JJ, Sager PT, de Groot E et al. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005: 149: 234-239.
39. Charlton-Menys V, Durrington PN. Squalene synthase inhibitors: Clinical pharmacology and cholesterol-lowering potential. Drugs 2007: 67: 11-16.
40. Biller SA, Neuenschwander K, Ponpipom MM et al. Squalene Synthase Inhibitors. Curr Pharm Des 1996: 1-40.
41. Sharma A, Slugg PH, Hammett JL et al. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol 1998: 38: 1116-1121.
42. Flint OP, Masters BA, Gregg RE et al. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997: 145: 91-98.
43. Masters BA, Palmoski MJ, Flint OP et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995: 131: 163-174.
44. Nishimoto T, Tozawa R, Amano Y et al. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol 2003: 66: 2133-2139.
45. de Montellano PR, Wei JS, Castillo R et al. Inhibition of squalene synthetase by farnesyl pyrophosphate analogues. J Med Chem 1977: 20: 243-249.
46. Bergstrom JD, Kurtz MM, Rew DJ et al. Zaragozic acids: A family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci U S A 1993: 90: 80-84.
47. Vaidya S, Bostedor R, Kurtz MM et al. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. Arch Biochem Biophys 1998: 355: 84-92.
48. Bostedor RG, Karkas JD, Arison BH et al. Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. J Biol Chem 1997: 272: 9197-9203.
49. Bedi M, Niesen M, Lopez D. Inhibition of squalene synthase upregulates PCSK9 expression in rat liver. Arch Biochem Biophys 2007: 470(2): 116-119.
50. Amin D, Rutledge RZ, Needle SN et al. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther 1997: 281: 746-752.
51. Ugawa T, Kakuta H, Moritani H et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol 2000: 131: 63-70.
52. Ugawa T, Kakuta H, Moritani H et al. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model. Br J Pharmacol 2002: 135: 1572-1578.
53. Amano Y, Nishimoto T, Tozawa R et al. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur J Pharmacol 2003: 466: 155-161.
54. Piper E, Price G, Chen Y. TAK-475, a squalene synthase inhibitor improves lipid profile in hyperlipidemic subjects. Circulation 2006: 114: II-288.
55. Perez A, Kupfer K, Chen Y. Addition of TAK-475 to atorvastatin provides incremental lipid benefits. Circulation 2006: 114: II-113.
56. Gibbs E. FDA tells Takeda to stop some TAK-475 trials. Tokyo: Reuters, 2007. Retrieved October 29, 2007, from http://www. reuters.com/article/ health-SP/idUST17428120071029:2
57. Limited TPC. Takeda Provides Update on Development Status of TAK-475, An Investigational Compound for Treatment of Hypercholesterolemia. Retrieved October 29, 2007, from http://www.takeda.com/press/ article_28386.html.
58. Takeda Pharmaceutical Company Limited. Discontinuation of Development of TAK-475. A Compound for Treatment of Hypercholesterolemia. Retrieved March 28, 2008, from http://www.takedacom/press/article_29153html.
59. Tozawa R, Ishibashi S, Osuga J et al. Embryonic lethality and defective neural tube closure in mice lacking squalene synthase. J Biol Chem 1999: 274: 30843-30848.
60. Okazaki H, Tazoe F, Okazaki S et al. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver. J Lipid Res 2006: 47: 1950-1958.
61. Yu Y, Wyszynski DF, Waterworth DM et al. Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia. J Lipid Res 2005: 46: 2202-2213.
62. Naoumova RP, Bonney SA, Eichenbaum-Voline S et al. Confirmed locus on chromosome 11p and candidate loci on 6q and 8p for the triglyceride and cholesterol traits of combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003: 23: 2070-2077.
63. Bonne AC, den Bieman MG, Gillissen GF et al. Chromosomal localization of genes involved in biosynthesis, metabolism or transport of cholesterol in the rat. Cytogenet Genome Res 2002: 97: 183-186.
64. Kato N, Tamada T, Nabika T et al. Identification of quantitative trait loci for serum cholesterol levels in stroke-prone spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 2000: 20: 223-229.
65. Bonne AC, den Bieman MG, Gillissen GF et al. Quantitative trait loci influencing blood and liver cholesterol concentration in rats. Arterioscler Thromb Vasc Biol 2002: 22: 2072-2079.
66. Engert JC, Lemire M, Faith J et al. Identification of a chromosome 8p locus for early-onset coronary heart disease in a French Canadian population. Eur J Hum Genet 2008: 16: 105-114.
67. Guan G, Dai P, Shechter I. Differential transcriptional regulation of the human squalene synthase gene by sterol regulatory element-binding proteins (SREBP) 1a and 2 and involvement of 5'DNA sequence elements in the regulation. J Biol Chem 1998: 273: 12526-12535.
68. Giglio S, Broman KW, Matsumoto N et al. Olfactory receptor-gene clusters, genomic-inversion polymorphisms, and common chromosome rearrangements. Am J Hum Genet 2001: 68: 874-883.
69. Graw SL, Sample T, Bleskan J et al. Cloning, sequencing, and analysis of inv8 chromosome breakpoints associated with recombinant 8 syndrome. Am J Hum Genet 2000: 66: 1138-1144.
70. Sugawara H, Harada N, Ida T et al. Complex low-copy repeats associated with a common polymorphic inversion at human chromosome 8p23. Genomics 2003: 82: 238-244.
71. Chen GK, Slaten E, Ophoff RA et al. Accommodating chromosome inversions in linkage analysis. Am J Hum Genet 2006: 79: 238-251.
72. International HapMap Consortium. A haplotype map of the human genome. Nature 2005: 437: 1299-1320.
73. Johnson GC, Esposito L, Barratt BJ et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001: 29: 233-237.
74. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 2002: 296: 2225-2229.
75. Nwokoro NA, Wassif CA, Porter FD. Genetic disorders of cholesterol biosynthesis in mice and humans. Mol Genet Metab 2001: 74: 105-119.
76. Herman GE. Disorders of cholesterol biosynthesis: Prototypic metabolic malformation syndromes. Hum Mol Genet 2003: 12 Spec No 1: R75-R88.
77. Mori M, Li G, Abe I et al. Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya cataract rat. J Clin Invest 2006: 116: 395-404.
78. Willer CJ, Sanna S, Jackson AU et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008: 40(2): 161-169.
79. Kathiresan S, Melander O, Guiducci C et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008: 40: 189-197.
80. Kooner JS, Chambers JC, Aguilar-Salinas CA et al. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet 2008: 40: 149-151.
81. Herbert A, Gerry NP, McQueen MB et al. A common genetic variant is associated with adult and childhood obesity. Science 2006: 312: 279-283.
82. Saxena R, Voight BF, Lyssenko V et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007: 316(5829): 1331-1336.
83. Keating BJ, Bhangale T, Price TS et al. Concept and design of a custom 50K SNP array for large-scale interrogation of vascular disease cohorts (abstract 1708). Presented at the annual meeting of the American Society of Human Genetics, October 24, 2007, San Diego, California.
84. Do R, ParéG, Montpetit A et al. The K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population. Hum Mutat 2008: 29: 689-694.
85. Serre D, Montpetit A, Pare G et al. Correction of population stratification in large multi-ethnic association studies. PLoS ONE 2008: 3: E1382.
86. Chasman DI, Posada D, Subrahmanyan L et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004: 291: 2821-2827.
87. Thompson JF, Man M, Johnson KJ et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005: 5: 352-358.
88. Peltola P, Pihlajamaki J, Koutnikova H et al. Visceral obesity is associated with high levels of serum squalene. Obesity (Silver Spring) 2006: 14: 1155-1163.
89. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: Server and survey. Nucleic Acids Res 2002: 30: 3894-3900.
90. Menys VC, Durrington PN. Squalene synthase inhibitors. Br J Pharmacol 2003: 139: 881-882.
91. Zondervan KT, Cardon LR. The complex interplay among factors that influence allelic association. Nat Rev Genet 2004: 5: 89-100.
92. Barrett JC, Fry B, Maller J et al. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005: 21: 263-265.
93. Cartegni L, Wang J, Zhu Z et al. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003: 31: 3568-3571.